Mechanism-based treatments for Alzheimer's disease

Dialogues in Clinical Neuroscience

Volumn 11, Issue 2, 2009, Pages 159-169

  Davies, Peter ^a   Koppel, Jeremy ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

amyloid; Aggregation; Antibody; Inflammation; Protein kinase; Secretase; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; CELECOXIB; FLURBIPROFEN; HYDROXYCHLOROQUINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PRESENILIN 1; PROTEIN INHIBITOR; ROFECOXIB; TRIFLUSAL;

ALZHEIMER DISEASE; ASTROCYTOSIS; CLINICAL TRIAL; DRUG INHIBITION; GLIOSIS; HUMAN; MEDICAL RESEARCH; MOLECULAR CLONING; NEUROFIBRILLARY TANGLE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ENZYME INHIBITORS; HUMANS; NEUROFIBRILLARY TANGLES; NEUROIMMUNOMODULATION; PHOSPHORYLATION; SENILE PLAQUES; TAU PROTEINS;

EID: 67650783216     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383-388.
2. Hardy J. Molecular genetics of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:13-17.
3. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
4. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387-390. (Pubitemid 28093512)
5. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775-778.
6. Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet. 1997;6:1639-1646.
7. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732-742.
8. Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27:686-695.
9. Kakuda N, Funamoto S, Yagishita S, et al. Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J Biol Chem. 2006;281:14776-14786. (Pubitemid 43855183)
10. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006;9(3 suppl):151-153. (Pubitemid 44253307)
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-842.
12. Malm T, Ort M, Tahtivaara L, et al. beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A. 2006;103:8852-8857. (Pubitemid 43878107)
13. Winkler J, Connor DJ, Frautschy SA, et al. Lack of long-term effects after beta-amyloid protein injections in rat brain. Neurobiol Aging. 1994;15:601-607. (Pubitemid 24287331)
14. Walsh DM, Klyubin I, Shankar GM, et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005;33(Pt 5):1087-1090. (Pubitemid 41659119)
15. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789-791.
16. Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007;4:473-478. (Pubitemid 47416642)
17. Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67:1757-1763. (Pubitemid 44900749)
18. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-741. (Pubitemid 129515714)
19. Haniu M, Denis P, Young Y, et al. Characterization of Alzheimer's beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem. 2000;275:21099-21106 (Pubitemid 30481802)
20. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10:1317-1324. (Pubitemid 32600485)
21. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233-234. (Pubitemid 32194867)
22. Moore KP, Zhu H, Rajapakse HA, et al. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett. 2007;17:5831-5835. (Pubitemid 47446223)
23. Dominguez DI, Hartmann D, De Strooper B. BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. Neurodegener Dis. 2004;1:168-174. (Pubitemid 39551793)
24. Lindsley SR, Moore KP, Rajapakse HA, et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett. 2007;17:4057-4061.
25. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693-11709. (Pubitemid 43098462)
26. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629-639. (Pubitemid 27511773)
27. Hartmann D, Tournoy J, Saftig P, Annaert W, De Strooper B. Implication of APP secretases in notch signaling. J Mol Neurosci. 2001;17:171-181. (Pubitemid 33063521)
28. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23-36. (Pubitemid 38456965)
29. Shen J, Kelleher RJ, 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007;104:403-409.
30. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602-604. (Pubitemid 43739900)
31. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031-1038.
32. Zou K, Kim D, Kakio A, Byun K, et al. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem. 2003;87:609-619. (Pubitemid 37310627)
33. Irie K, Murakami K, Masuda Y, Met al. The toxic conformation of the 42-residue amyloid beta peptide and its relevance to oxidative stress in Alzheimer's disease. Mini Rev Med Chem. 2007;7:1001-1008.
34. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177. (Pubitemid 29327547)
35. Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008;28:6787-6793.
36. Buckwalter MS, Coleman BS, Buttini M, et al. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J Neurosci. 2006;26:11437-11441. (Pubitemid 44772174)
37. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448-452. (Pubitemid 36460079)
38. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose! Am J Pathol. 2006;169:738-739. (Pubitemid 44411941)
39. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11-20. (Pubitemid 38200585)
40. Kim HD, Cao Y, Kong FK, Van Kampen KR, et al. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine. 2005;23:2977-2986. (Pubitemid 40462436)
41. Grubeck-Loebenstein B, Blasko I, Marx FK, Trieb I. Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. 2000;23:114.
42. Seitz RJ, Heininger K, Schwendemann G, Toyka KV, Wechsler W. The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system. Acta Neuropathol. 1985;68:15-21. (Pubitemid 16246441)
43. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24. (Pubitemid 40617823)
44. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144-6151. (Pubitemid 38891105)
45. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850-8855.
46. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-919 (Pubitemid 30644751)
47. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int. 2006;49:190-194. (Pubitemid 43867077)
48. Deane R, Sagare A, Hamm K, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci. 2005;25:11495-11503. (Pubitemid 43102486)
49. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909-918.
50. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol. 2009;65:24-31.
51. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943-948. (Pubitemid 34665486)
52. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′- splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702-705. (Pubitemid 28289662)
53. Morris HR, Khan MN, Janssen JC, Brown JM, Perez-Tur J, Baker M, et al. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol. 2001;58:1813-1816. (Pubitemid 33044247)
54. Morris HR, Perez-Tur J, Janssen JC, et al. Mutation in the tau exon 10 splice site region in familial frontotemporal dementia. Ann Neurol. 1999;45:270-271. (Pubitemid 29072380)
55. Hardy J. The relationship between amyloid and tau. J Mol Neurosci. 2003;20:203-206.
56. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534-542.
57. Liu T, Perry G, Chan HW, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem. 2004;88:554-563. (Pubitemid 38140200)
58. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750-754. (Pubitemid 46717684)
59. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364-6369. (Pubitemid 34493317)
60. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell. 1995;6:1887-1902.
61. Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564-569.
62. Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1990;87:5827-5831. (Pubitemid 20240381)
63. Congdon EE, Duff KE. Is tau aggregation toxic or protective? J Alzheimers Dis. 2008;14:453-457.
64. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913-4917. (Pubitemid 16075509)
65. Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry. 2004;43:1694-1703. (Pubitemid 38200576)
66. Wilson DM, Binder LI. Polymerization of microtubule-associated protein tau under near-physiological conditions. J Biol Chem. 1995;270:24306-24314.
67. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol. 1997;150:2181-2195.
68. Ksiezak-Reding H, Liu WK, Yen SH. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 1992;597:209-219. (Pubitemid 23003689)
69. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159-168.
70. Alonso A, Zaidi T, Novak M, Grundke-lqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A. 2001;98:6923-6928. (Pubitemid 32538318)
71. Pelech SL. Networking with proline-directed protein kinases implicated in tau phosphorylation. Neurobiol Aging. 1995;16:247-56; discussion 57-61.
72. Liu F, Liang Z, Shi J, et al. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett. 2006;580:6269-6274. (Pubitemid 44666812)
73. Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem. 1997;121:179-188. (Pubitemid 27096190)
74. Sperber BR, Leight S, Goedert M, Lee VM. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett. 1995;197:149-153
75. Spittaels K, Van den Haute C, Van Dorpe J, et al. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem. 2000;275:41340-41349. (Pubitemid 32054968)
76. Muyllaert D, Terwel D, Borghgraef P, Devijver H, Dewachter I, Van Leuven F. Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology. Rev Neurol (Paris). 2006;162:903-907. (Pubitemid 44495481)
77. Nuydens R, Van Den Kieboom G, Nolten C, et al. Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau. Neurobiol Dis. 2002;9:38-48. (Pubitemid 34174563)
78. Avila J, Hernandez F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother. 2007;7:1527-1533.
79. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007;190:359-360.
80. Molchan SE, Manji H, Chen G, et al. Effects of chronic lithium treatment on platelet PKC isozymes in Alzheimer's and elderly control subjects. Neurosci Lett. 1993;162:187-191. (Pubitemid 23347978)
81. Kelwala S, Pomara N, Stanley M, Sitaram N, Gershon S. Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. J Clin Psychiatry. 1984;45:342-344. (Pubitemid 14066279)
82. Randels PM, Marco LA, Hanspal NS, Robinson B. Possible lithium-induced extrapyramidal effects in Alzheimer's disease. Hillside J Clin Psychiatry. 1984;6:117-721. (Pubitemid 14049808)
83. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell. 2007;18:5060-5068. (Pubitemid 350246705)
84. Steinhilb ML, Dias-Santagata D, Mulkearns EE, et al. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res. 2007;85:1271-1278. (Pubitemid 46724370)
85. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:6990-6995. (Pubitemid 40675429)
86. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci. 2007;27:1981-1991. (Pubitemid 46310321)
87. Tariot PN. Clinical trials of amyloid-based therapies for Alzheimer's disease. CNS Spectr. 2007;12(1 suppl 1):7-10.
88. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta. 2004;1697:137-142.
89. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2004;10:452-458. (Pubitemid 39209212)
90. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471-483. (Pubitemid 37494698)
91. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615-622. (Pubitemid 129516324)
92. Tandon A, Yu H, Wang L, Rogaeva E, et al. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem. 2003;86:572-581. (Pubitemid 36897438)
93. Noble W, Olm V, Takata K, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003;38:555-565. (Pubitemid 36645031)
94. Roder HM, Hutton ML. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin Ther Targets. 2007;11:435-442.
95. Le Corre S, Klafki HW, Plesnila N, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A. 2006;103:9673-9678. (Pubitemid 43955883)
96. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2008;15:157-168.
97. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432. (Pubitemid 26324038)
98. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994;44:227-232.
99. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995 Jul-Aug;16:523-530.
100. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588-593.
101. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204-1215. (Pubitemid 40720980)
102. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826. (Pubitemid 37430117)
103. Aisen PS, Thal U, Ferris SH, et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008;5:73-82.
104. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896-905. (Pubitemid 352008472)
105. Group AR, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800-1808. (Pubitemid 46791392)
106. Gomez-Isla T, Blesa R, Boada M, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008;22:21-29. (Pubitemid 351651394)
107. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358:455-460. (Pubitemid 32769852)
108. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216. (Pubitemid 33051236)
109. Geerts H. Drug evaluation: (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs. 2007;10:121-133. (Pubitemid 46438443)
110. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23:159-169. (Pubitemid 38980441)
111. Herrup K, Yang Y. Pictures in molecular medicine: contemplating Alzheimer's disease as cancer: a loss of cell-cycle control. Trends Mol Med. 2001;7:527. (Pubitemid 33021684)
112. Vincent I, Pae CI, Hallows JL. The cell cycle and human neurodegenerative disease. Prog Cell Cycle Res. 2003;5:31-41.
113. Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease? J Cell Biol. 1996;132:413-425.
114. Park KH, Hallows JL, Chakrabarty P, Davies P, Vincent I. Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J Neurosci. 2007;27:2969-2978. (Pubitemid 46438995)
115. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923. (Pubitemid 23275809)
116. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472. (Pubitemid 23230526)
117. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981. (Pubitemid 23069980)
118. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol. 1994;53:429-437. (Pubitemid 24276801)
119. Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer's disease. Curr Opin Biotechnol. 1994;5:663-667.
120. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet. 2002;70:708-717. (Pubitemid 34177924)
121. Li YJ, Pericak-Vance MA, Haines JL, et al. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics. 2004;5:209-213.
122. Burwick RM, Ramsay PP, Haines JL, Hauser SL, Oksenberg JR, Pericak-Vance MA, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology. 2006;66:1373-1383.